Tubridge® Holds Fifth Presentation at World Live Neurovascular Conference (WLNC)

Barcelona, Spain – The World Live Neurovascular Conference (WLNC) was held here on May 1, 2019, bringing together the world’s top neurovascular internationalists to conduct exchanges and share expertise. The globally influential scientific conference in the field of interventional neurology aimed to showcase the latest progress of clinical researches in the field with the techniques at the forefront of development. The Tubridge® Vascular Reconstruction Device (“Tubridge®”) of MicroPort NeuroTech (Shanghai) Co., Ltd. (“MicroPort® NeuroTech”), which is a blood flow diverting device, held its fifth presentation during the Live Case session of WLNC since 2014.

At 9 am on May 3 local time, the team led by Prof. Yi Xu and Qinghai Huang at Changhai Hospital of Shanghai presented four challenging live cases using Tubridge®, with the simultaneous explanation given by Prof. Jianmin Liu and Prof. Bo Hong at WLNC in Barcelona. The lesion locations of the four operations were vertebrobasilar aneurysms、ICA Large aneurysm of ophthalmic segment、ICA cavernous segment aneurysm and vertebral artery (V4 segment) dissecting aneurysm respectively. Tubridge® demonstrated its outstanding performance in all the cases featuring complex vascular environment, with immediately significant results after its delivery, deployment and perfect vessel wall apposition. The healthcare professionals in attendance paid extraordinary attention to the brilliant performance of Tubridge®, so much so that they made many enquiries with Prof. Liu and Prof. Hong about the technological characteristics of Tubridge®. Both the speakers and the audience had heated discussions with respects to how the Chinese surgeons planned the live cases, what they needed to consider when deploying Tubridge®, its indications, the therapeutic indications of the assisted coil, as well as whether the live cases should be performed in phases.

On the eve of WLNC, the neurovascular internationalist team from Changhai Hospital of Shanghai also presented the follow-up results of the live cases showcased at last year’s edition of WLNC. Tubridge® was applied in the two cases to treat vertebral artery dissection aneurysm and bridging-treat basilar artery aneurysm respectively. The follow-ups showed complete blocking of the aneurysms and satisfactory surgical results. The smart-made-in-China Tubridge® reconfirmed its efficacy and safety in the treatment of intracranial aneurysms with evidence.

Tubridge® is an innovative result of MicroPort® NeuroTech’s 12-year independent R&D to treat intracranial large and huge aneurysms. It obtained the registration approval from National Medical Products Administration of China (NMPA) in March 2018 as the only Chinese-made blood flow diverting device produced in China. From 2014 on, WLNC witnessed the R&D, launch and clinical applications of Tubridge® along with the endorsements it received from global neurovascular interventionalists. As a leading innovation-driven high-end medical device maker from China, MicroPort® NeuroTech will continue to help rev up the development of China’s high-end medical devices within the interventional neurology landscape and provide more comprehensive cerebrovascular interventional solutions.